Skip to main content

Filariasis: Current Status, Treatment and Recent Advances in Drug Development

Buy Article:

$68.00 + tax (Refund Policy)

Lymphatic filariasis, onchocerciasis and loiasis caused by human filarial nematodes are diseases of tropical and subtropical countries causing considerable morbidity. The available control strategies have significant limitations such that current drugs are ineffective against macrofilariae (adult worms), require repeated and prolonged treatment over years and are threatened by emergence of drug resistance. Due to this concern, these diseases are the focus of renewed scientific interest and much has been done in filariasis research in the past decade. This review summarizes the current status of filariasis, different control strategies, recent advances in antifilarial chemotherapy including currently used drugs, their pros and cons, their mechanism of action, and recently discovered targets and prototypes.





Keywords: Brugia malayi; Onchocerca volvulus; Wuchereria bancrofti; filariasis control programs; loiasis; lymphatic filariasis; onchocerciasis; target based antifilarial agents

Document Type: Research Article

Publication date: 01 May 2011

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content